Skip to main content

Long-term Follow-up

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sorrento Therapeutics
Sorrento TherapeuticsCA - San Diego
1 program
Gene-Modified Cell TherapyN/A1 trial
Active Trials
NCT05472649Enrolling By Invitation1Est. May 2037

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Sorrento TherapeuticsGene-Modified Cell Therapy

Clinical Trials (1)

Total enrollment: 1 patients across 1 trials

NCT05472649Sorrento TherapeuticsGene-Modified Cell Therapy

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Start: Jun 2021Est. completion: May 20371 patients
N/AEnrolling By Invitation

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.